Agenus Inc.
Agenus Inc.
Your view on AGEN
Overview
What the company does, where it operates, and who runs it.
About Agenus Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Garo H. Armen
- Headquarters
- 3 Forbes Road, Lexington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Garo H. Armen
- Headquarters
- 3 Forbes Road, Lexington, MA, US
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.
In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks.
It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Agenus Inc. from FRC's valuation model, read against the market price. AGEN last traded at $6.40, 8.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Agenus Inc.. Starting points for Agenus Inc.: P/E 8.6, EPS $0.49, beta 1.52 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Agenus Inc.. Agenus Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Agenus Inc.. Trailing twelve-month EPS for Agenus Inc. stands at $0.49. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$25.00
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.17 | -$0.23 | $0.63 | -$0.54 |
| Low estimate | -$0.17 | -$0.23 | $0.58 | -$0.84 |
| High estimate | -$0.17 | -$0.22 | $0.68 | -$0.23 |
| No. of analysts | 1 | 1 | 2 | 2 |
| Year-ago EPS | $0.561 | $1.021 | -$0.001 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $31.07M | $25.45M | $130.95M | $121.30M |
| Low estimate | $30.91M | $25.32M | $130.50M | $96.81M |
| High estimate | $31.24M | $25.58M | $131.40M | $145.79M |
| No. of analysts | 1 | 1 | 2 | 2 |
| Year-ago revenue | $34.20M | $33.74M | $114.20M | — |
| Growth | -9.1% | -24.6% | +14.7% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 19, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Agenus Inc.. Agenus Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABOSAcumen Pharmaceuticals, Inc.Biotechnology$14M
- FATEFate Therapeutics, Inc.Biotechnology$122M
- HURATuHURA Biosciences, Inc.Biotechnology$87M
- INOInovio Pharmaceuticals, Inc.Biotechnology$117M
- IRDOpus Genetics, Inc.Biotechnology$326M
- PLRXPliant Therapeutics, Inc.Biotechnology$41M
- SEERSeer, Inc.Biotechnology$80M
- TTRXTurn Therapeutics Inc.Biotechnology$272M
More Biotechnology companies
- SGMTSagimet Biosciences Inc.NASDAQ$711M
- SGPSpyGlass Pharma, Inc. Common StockNASDAQ$993M
- SHJBFShanghai Junshi Biosciences Co., Ltd.OTC$4.1B
- SIGYSigyn Therapeutics, Inc.OTC
- SILOSilo Pharma, Inc.NASDAQ$2M
- SIONSionna Therapeutics, Inc.NASDAQ$134M
- SKYESkye Bioscience, Inc.NASDAQ$4M
- SLBTSL Science Holding LtdNASDAQ$370M
- SLDBSolid Biosciences Inc.NASDAQ$709M
- SLGLSol-Gel Technologies Ltd.NASDAQ$175M
- SLNSilence Therapeutics plcNASDAQ$936M
- SLNCFSilence Therapeutics plcOTC$227M
ETFs holding Agenus Inc.
% of the fund
- IWMiShares Russell 2000 ETF$76.6B in assets0.01%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- IWNiShares Russell 2000 Value ETF$13.9B in assets0.01%
- QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.51%
- VMO.TOVanguard Global Momentum Factor ETF$477M in assets0.06%
- VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.01%
- RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%
Largest holders first, then the funds most concentrated in AGEN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Agenus Inc., and how their positions are changing. At a $289.6M market value, institutional positions materially move Agenus Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Agenus Inc. executives and directors. Shares of Agenus Inc. have traded between $1.38 and $7.34 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Agenus Inc.. Coverage tracks Agenus Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Agenus Inc.